OverviewSuggest Edit

Axcella Health is a biotechnology company that researches and develops novel multifactorial interventions to support health and address dysregulated metabolism. The company develops its products based on its AXA Development Platform. It offers AXA1665 for use in treating hepatic encephalopathy, AXA1125 and AXA1957 to treat non-alcoholic fatty liver disease, AXA2678 for use in treating immobilization-induced acute muscle atrophy, and AXA4010 to target multiple biological pathways. 

TypePublic
Founded2010
HQCambridge, MA, US
Websiteaxcellahealth.com
Employee Ratings4

Latest Updates

Employees (est.) (Jun 2019)49
Job Openings5
Share Price (May 2022)$1.8(+4%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Axcella Health

David R. Epstein

David R. Epstein

Director
Bill Hinshaw

Bill Hinshaw

President & Chief Executive Officer, Director
Alison Schecter

Alison Schecter

President, Research and Development
William D. Baird

William D. Baird

Director
Sam Rebello

Sam Rebello

VP, Head of Development Sciences
Laurent Chardonnet

Laurent Chardonnet

Senior Vice President and Chief Financial Officer
Show more

Axcella Health Office Locations

Axcella Health has an office in Cambridge
Cambridge, MA, US (HQ)
5 Memorial Dr
Show all (1)

Axcella Health Financials and Metrics

Axcella Health Revenue

USD

Net income (FY, 2020)

(56.5m)

EBIT (FY, 2020)

(53.8m)

Market capitalization (6-May-2022)

71.6m

Closing stock price (6-May-2022)

1.8

Cash (31-Dec-2020)

71.6m

EV

25.2m
Axcella Health's current market capitalization is $71.6 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

6.0m8.4m15.8m16.8m

R&D expense

22.9m25.5m41.7m37.0m

Operating expense total

28.9m33.9m57.4m53.8m

EBIT

(28.9m)(33.9m)(57.4m)(53.8m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

3.5m4.7m4.8m4.1m4.6m

R&D expense

7.6m9.3m12.2m10.3m8.6m

Operating expense total

11.0m14.1m17.0m14.5m13.2m

EBIT

(11.0m)(14.1m)(17.0m)(14.5m)(13.2m)
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

46.8m79.5m92.1m71.6m

Accounts Receivable

255.0k835.0k

Prepaid Expenses

1.5m1.7m

Current Assets

47.1m80.3m93.5m109.0m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

66.8m117.9m105.4m75.5m121.3m

Prepaid Expenses

1.7m3.5m3.0m1.3m2.9m

Current Assets

68.4m121.4m108.3m76.8m124.2m

PP&E

920.0k758.0k659.0k477.0k357.0k
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(30.9m)(36.1m)(59.0m)(56.5m)

Depreciation and Amortization

1.4m1.1m662.0k419.0k

Accounts Payable

40.0k595.0k366.0k311.0k

Cash From Operating Activities

(26.9m)(30.7m)(51.0m)(49.8m)
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(11.6m)(26.0m)(43.3m)(15.0m)(28.9m)

Depreciation and Amortization

518.0k131.0k

Accounts Payable

858.0k111.0k2.0m(286.0k)(523.0k)

Cash From Operating Activities

(12.2m)(25.4m)(37.6m)(16.5m)(29.0m)
USDFY, 2017

Financial Leverage

-0.4 x
Show all financial metrics

Axcella Health Acquisitions / Subsidiaries

Company NameDateDeal Size
Acora Nutrition LLC
Axcella Health Securities Corporation

Axcella Health Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Axcella Health Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Axcella Health Online and Social Media Presence

Embed Graph

Axcella Health News and Updates

Axcella Health Reports First Quarter 2019 Financial Results and Provides Company Update

CAMBRIDGE, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Axcella Health, Axcella Health Inc. (Nasdaq: AXLA) (“Axcella” or the “Company”), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today an…

Axcella Health Blogs

Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH

Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-003 in Subjects With Presumed NASH Content Import Mon, 08/16/2021 - 07:58 Axcella Announces Publication in The American Journal of Gastroenterology of Positive Results from AXA1125-00…

Axcella Reports Second Quarter Financial Results and Provides Business Update

Initiated EMMPOWER Phase 2 clinical trial of AXA1665 for the reduction in risk of recurrent OHE Initiated EMMPACT Phase 2b clinical trial of AXA1125 for the treatment of NASH Presented data at key medical congresses Enhanced management team with the addition of Chief People Officer Company to host

Axcella to Report Second Quarter 2021 Financial Results on July 29, 2021

Conference call to take place at 8:30 a.m. ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 22, 2021-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today

Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665

Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665 Content Import Wed, 06/30/2021 - 07:28 Axcella Announces Initiation of EMMPOWER℠ Phase 2 Clinical Trial of AXA1665 June 30, 2021 at 7:28 AM EDT This release is a backfill from a News W…

Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021

Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presentation at DDW 2021 Content Import Mon, 05/24/2021 - 07:28 Positive Clinical Data About Axcella’s AXA1665 Candidate for Overt Hepatic Encephalopathy Highlighted in Oral Presen…

Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125

Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125 jennifer.segal… Tue, 05/11/2021 - 07:28 Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125 May 11, 2021 at 7:28 AM EDT This release is a backfill from a News W…
Show more

Axcella Health Frequently Asked Questions

  • When was Axcella Health founded?

    Axcella Health was founded in 2010.

  • Who are Axcella Health key executives?

    Axcella Health's key executives are David R. Epstein, Bill Hinshaw and Alison Schecter.

  • How many employees does Axcella Health have?

    Axcella Health has 49 employees.

  • Who are Axcella Health competitors?

    Competitors of Axcella Health include Elektrofi, Jubilant Pharma and MyMeds&Me.

  • Where is Axcella Health headquarters?

    Axcella Health headquarters is located at 5 Memorial Dr, Cambridge.

  • Where are Axcella Health offices?

    Axcella Health has an office in Cambridge.

  • How many offices does Axcella Health have?

    Axcella Health has 1 office.